CMS proposes narrowly covering controversial
Alzheimer’s drug Aduhelm for patients in clinical trials
CMS is proposing to have Medicare cover controversial
Alzheimer's disease drug Aduhelm, but only for patients in qualifying
clinical trials. |
Tuesday, January 11, 2022
CMS proposes restricting Aduhelm coverage to patients in clinical trials
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment